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ABSTRACT
Objectives: To address the limited long-term outcome
data for catheter ablation (CA) of persistent atrial
fibrillation (PeAF), we analysed consecutive ablations
performed at our centre from 1 January 2008 to 31
December 2010 and followed patients prospectively
until January 2014.
Methods: Both arrhythmia recurrence and symptom
relief were assessed. Follow-up data were collected
from hospital records, supplemented by data from
general practitioners and referring hospitals. At the end
of the follow-up period, all patients were contacted by
phone to determine their up-to-date clinical condition.
Results: 188 consecutive patients with PeAF (157
male, mean age 57.3±9.7 years, 20% with long-
standing PeAF) underwent a mean of 1.75 procedures
(range 1–4). Telephone follow-up was achieved for
77% of surviving patients. Over a mean follow-up of
46±16 months (range 4–72), 139 (75%) patients
experienced arrhythmia recurrence after a single
procedure and 90 (48%) after their final procedure.
Median time to first recurrence was 210 days (range
91–1850). 71% of recurrences were within the first
year following ablation and 91% within 2 years. At final
follow-up, 82% of patients reported symptomatic
improvement. 7 (2.3%) major complications occurred,
and there was no procedure-related death or stroke.
Conclusions: CA for PeAF is safe with a low rate of
complications. Over a follow-up period of up to
6 years, a large majority of patients experience
significant symptomatic improvement but recurrence
after the initial procedure is the norm rather than the
exception. 2 years’ follow-up is sufficient to observe
90% of AF recurrences, but recurrence can occur even
after 5 years’ remission.
BACKGROUND
Catheter ablation (CA) for atrial ﬁbrillation
(AF) is now commonly used for a disease that
has been described as an emerging medical
epidemic.1 Between 2005 and 2009, the
number of CAs performed in the UK
increased by a factor of 10 (UK National
Cardiac Audit data, personal communication).
The current European Society of Cardiology
guidelines give a class 1a recommendation for
its use in drug refractory paroxysmal AF
(PAF).2 The evidence base for PAF is well
established with superior efﬁcacy over antiar-
rhythmic drugs demonstrated in several clin-
ical trials.3 For persistent AF (PeAF), the
situation is less clear as the evidence base is
KEY QUESTIONS
What is already known about this subject?
▸ Freedom from recurrent atrial tachyarrhythmia is
less common after catheter ablation of persist-
ent, rather than paroxysmal, atrial fibrillation
(AF). There is a belief that short-term success
frequently is not maintained over time but there
are few published studies of long-term results of
persistent AF (PeAF) ablation, and the results in
these studies vary greatly.
What does this study add?
▸ This study provides data on outcomes after
catheter ablation of PeAF over a 6-year period
and is likely to more closely match real-life
experience than the few previous studies which
have originated from highly specialised and
internationally renowned centres. In addition to
arrhythmic outcomes, this is the first such study
to look at the impact of ablation on patients’
health status.
How might this impact on clinical practice?
▸ The term curative AF ablation is often used but,
from our results, would appear to be misleading
for PeAF. Patients should be aware that complete
freedom from recurrent arrhythmia is an excep-
tion, rather than the norm. That notwithstanding,
the indication for catheter ablation is the relief of
AF symptoms rather than freedom from recur-
rent AF and our results show that this is achiev-
able for the majority of patients. Operators may
consider using three-dimensional mapping tech-
niques that combine integration of CT left atrial
images, as our results suggest that this has a
significant impact on long-term success.
Wynn GJ, El-Kadri M, Haq I, et al. Open Heart 2016;3:e000394. doi:10.1136/openhrt-2015-000394 1
Arrhythmias and sudden death
weaker and a recent Cochrane review found insufﬁcient
evidence to support the use of CA for PeAF.4 However,
more than 40% of procedures performed worldwide are
reported to be for patients with PeAF.5
Although recent randomised controlled trials (RCTs)
have shown superior efﬁcacy of CA compared with
medical therapy for patients with PeAF, the follow-up for
these trials is short.6 7 A recent meta-analysis of rando-
mised and non-RCTs of CA in PeAF found that the mean
follow-up was 13.5±6 months.8 One issue for both forms
of the disease is that early CA success does not always
translate into long-term freedom from AF.9 We reviewed
consecutive CA procedures performed for PeAF over a
3-year period at a single, high-volume centre in the UK
and followed up patients for a further 3 years in order to
provide up to 6 years of outcome data.
METHODS
Patients
Consecutive patients who underwent a ﬁrst-time CA for
PeAF at Liverpool Heart and Chest Hospital (LHCH)
during a 3-year period (01 January 2008 to 31 December
2010) were identiﬁed retrospectively and clinical notes
reviewed for procedural data. Patients were classiﬁed as
having PeAF if they had AF present continuously or had
episodes of AF lasting for longer than 7 days at a time or
requiring cardioversion, as speciﬁed by the published
guidelines at the time the study was initiated.10
Comprehensive demographic, medical history and pro-
cedural details were collected from the hospital notes
and electronic data storage systems. Data veriﬁcation was
performed for all outlying data points.
Follow-up
Clinical follow-up data were collected prospectively until
January 2014. Two clinicians, both of whom were inde-
pendent of the original procedure, reviewed the
follow-up data. Missing follow-up data were obtained by
contacting the patient’s base hospital and/or general
practitioner. Recurrence of AF was deemed to have
occurred whenever AF or atrial tachycardia was docu-
mented on resting ECG or during a period of monitor-
ing, or—in keeping with the real-world nature of this
study—if the responsible clinician treated the patient for
recurrence of AF without deﬁnitive proof, for example,
by performing repeat CA or starting new antiarrhythmic
medication because of the return of the patient’s typical
symptoms. Mortality data were obtained from the UK’s
central healthcare database (National Health Service
(NHS) Spine). For any patient who died during
follow-up, their general practitioner was contacted for
cause of death and further details. At the end of the
study, all patients were contacted by phone to invite
them to provide ﬁnal follow-up data. Telephone inter-
views were carried out using a standardised interview
template. To avoid loss of follow-up due to working pat-
terns or holidays, initial unsuccessful daytime contact
was followed up by repeated attempts in the evening and
at the weekend, spread out over a period of several
weeks. The study was approved by both the hospital and
regional research ethics committees.
Electrophysiological study
CA was performed under conscious sedation or general
anaesthesia. Antiarrhythmic drugs were stopped at least
ﬁve half-lives prior to the procedure, except for amiodar-
one which was generally continued. Postprocedural
anticoagulation was with warfarin with bridging low mole-
cular weight heparin (LMWH) used until the patient’s
international normalised ratio was ≥2. Preprocedural
transoesophageal echocardiography was carried out for
patients with AF without at least four preceding weeks of
therapeutic anticoagulation. In general, vascular access
was exclusively via the right femoral vein, with other
routes only used as required. A deﬂectable decapolar
catheter was positioned within the coronary sinus.
Trans-septal access was gained using a Brockenbrough or
Endrys needle under ﬂuoroscopic guidance with either
a single or double puncture. A variety of long sheaths
were used. Unfractionated heparin was used to maintain
an activated clotting time above 250–300 s. In all cases,
pulmonary vein isolation (PVI) was ﬁrst performed,
predominantly using a 3.5–4 mm irrigated tip radio-
frequency catheter with ﬂow rates between 12 and
30 mL/min, using a segmental ostial or wide area cir-
cumferential ablation (WACA) pattern. A 20-pole circu-
lar mapping catheter was used to measure electrical
activity within the pulmonary veins. The addition of
linear lesions and complex fractionated atrial electro-
gram (CFAE) ablation was according to operator prefer-
ence. Temperature limits were set to 50°C and ablation
power was limited to 25–30 W on the posterior left atrial
(LA) wall, 30–35 W on the anterior wall, roof and the
intervenous carina, 25 W in the coronary sinus and
50 W for cavotricuspid isthmus ablation. Ablation was
carried out either using a continuous dragging tech-
nique or individual point-by-point lesions of 20–40 s dur-
ation to achieve >75% attenuation of the local
electrogram. In three cases, PVI was performed using
the HD Mesh Ablator (C.R. Bard, Murray Hill, New
Jersey, USA) and in one case with the Arctic Front cryoa-
blation system (Medtronic, Minneapolis, Minnesota,
USA). In keeping with published guidance, PVI was
deﬁned as proven entrance block. For linear lesions,
excluding non-anchored lesions, the desired end point
was bidirectional conduction block, as veriﬁed with
appropriate pacing manoeuvres.11 The overall procedural
end point was completion of the attempted lesion sets
rather than termination of AF. Patients were monitored
overnight and routinely discharged the following day.
Statistical analysis
Discrete variables, including change in health status
which was treated as a dichotomous variable, are
described in terms of the frequency and proportion and
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compared using the χ2 or Fisher’s exact test. Continuous
variables are described as mean±SD, and compared
using unpaired t-tests for normally distributed data, or
median (IQR) and compared using Mann-Whitney U
test. Analyses were performed using IBM SPSS Statistics
software V.21. Survival data were plotted using the
Kaplan-Meier estimator. The log-rank test was used to
compare survival between groups. Univariable and mul-
tivariable predictors of AF recurrence were examined
using logistic regression using forward conditional mod-
elling. We prespeciﬁed that variables with a p value ≤0.1
would be included in the multivariable model and,
if necessary to maintain a minimum of 10 events per
variables, selected on a hierarchical basis. 12 Where
applicable, two-tailed tests were used in all analyses.
A p value ≤0.05 was considered signiﬁcant for all tests.
RESULTS
Patients and baseline characteristics
We identiﬁed 189 patients in whom ﬁrst-time percutan-
eous CA for PeAF was attempted during the study
period. Baseline characteristics are provided in table 1.
The mean duration of the current episode at the time
of CA was 7±14 months. Thirty-seven (20%) patients had
long-standing PeAF, deﬁned as 12 months’ continuous
AF with no period of sinus rhythm (SR) lasting
>24 hours. One hundred and forty-three (76%) patients
had at least one attempt at electrical cardioversion prior
to their CA, although only 70 (46%) maintained SR for
>1 month. The mean CHA2DS2-VASc score was 1.45±1.46
(median=1). One patient did not undergo ablation as
LA access was not possible, leaving 188 patients who
were eligible for follow-up.
Patient journey
In total, 332 CA procedures were performed or
attempted. Four procedures were abandoned before any
ablation was performed due to complications of trans-
septal puncture. Of these, three had no sequelae and
one resulted in a small pericardial effusion that was
managed conservatively. These procedures were included
in complication data but excluded when calculating
arrhythmic outcome data. Excluding abandoned proce-
dures, 105 (56%) patients underwent more than one CA
for AF. The ‘patient journey’ experienced in our patient
cohort is illustrated in ﬁgure 3. Eight patients (4%) were
eventually treated by implantation of a permanent pace-
maker and atrioventricular node ablation.
Follow-up
Clinical follow-up data were available for 186 of 188
eligible patients (98.5%). Mean follow-up time was of
46±16 months and ranged between 4 and 72 months.
Follow-up of >1 year was available for >95% of patients.
Eight patients died during follow-up. All deaths were
remote from CA, with the earliest occurring after
121 days. Five deaths were non-cardiovascular (two from
malignancy, one each from pulmonary ﬁbrosis, pneumo-
nia and renal failure) and three were cardiovascular in
aetiology (one each of aortic dissection, heart failure
and myocardial infarction). Three patients suffered a
stroke or transient ischaemic attack (TIA) during
follow-up, of whom two had complete neurological
recovery. All three had had warfarin stopped prior to
their event, in one because of intolerable side effects,
one because of low-risk proﬁle (CHA2DS2-VASc=0) and
one by the original referring physician despite a previ-
ous history of TIA. Data on antithrombotic medication
were available for 139 patients (75%), of whom 75
(54%) were taking oral anticoagulation (warfarin in 69,
direct thrombin/factor Xa inhibitor in 6), 27 (19%) an
antiplatelet agent and 37 (27%) no antithrombotic
therapy. Mean CHA2DS2-VASc was signiﬁcantly lower for
those on no therapy or an antiplatelet agent (no
therapy 0.65±0.75, antiplatelet 1.07±1.00, combined 0.83
±0.88) compared with those on an oral anticoagulant
(1.52±1.12, p<0.001).
Procedural complications
Seven patients experienced major complications. There
were three pericardial effusions requiring percutaneous
(n=2) or surgical (n=1) drainage, two inadvertent aortic
punctures, one phrenic nerve paralysis and one femoral
arterial pseudoaneurysm. Overall, this represents an inci-
dence of major complications of 2.1% per procedure
and 3.7% per patient. There were 18 minor complica-
tions of which 11 related to vascular access and 4 were
pericardial effusions managed conservatively. One
patient developed constrictive pericarditis 4 years after
his CA, which had been felt at the time to be uncompli-
cated. He was found to have a calciﬁed pericardial
haematoma on pericardiectomy that may have been an
unrecognised consequence of his CA procedure.
Table 1 Baseline characteristics
Characteristic
Male gender, n (%) 157 (83%)
Age (years) 57.3±9.7
Time since first AF diagnosis (months) 48±52
Long-standing PeAF, n (%) 37 (20%)
Left atrial anteroposterior diameter (mm) 44±6
Left ventricular systolic function, n (%)
Good (EF >50%) 156 (83%)
Mildly impaired (EF 40–49%) 12 (6%)
Moderately impaired (EF 30–39%) 9 (5%)
Severely impaired (EF <30%) 4 (2%)
Hypertension, n (%) 85 (45%)
Diabetes, n (%) 12 (6%)
Obstructive sleep apnoea, n (%) 11 (6%)
Previous stroke/transient
ischaemic attack, n (%)
8 (4%)
Ischaemic heart disease, n (%) 15 (8%)
AF, atrial fibrillation; EF, ejection fraction; PeAF, persistent AF.
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Ablation procedures
Of 188 index procedures, 91% were performed under
conscious sedation and 9% under general anaesthesia.
Conventional radiofrequency energy was used in 98% of
procedures. Ninety per cent of cases used three-
dimensional (3D) mapping systems: CARTO (Biosense
Webster, Diamond Bar, California, USA) in 60% and
Ensite NavX (St Jude Medical, St Paul, Minnesota, USA)
in 30%. In 96 (51%) cases, the 3D map of the LA was
integrated with a preoperative CT scan. Mean procedure
duration was 200±41 min, and mean ablation and ﬂuor-
oscopy times were 57±22 and 40+31 min, respectively.
Average radiation dose, in terms of dose-area-product,
was 5796±7634 mGy cm2.
PVI was performed in all cases, with additional linear
lesions deployed in 146 (78%) cases and CFAE ablation
in 62 (33%). PVI was by means of WACA in 109 cases,
segmental isolation in 75 and a mixed approach in
three. The most common LA linear lesion was a roof
line (117, 62%) followed by a ﬂoor line (72, 38%).
A mitral isthmus line was created in 37 (20%) cases.
A right atrial ﬂutter line was performed in 97 (52%)
patients. CFAE ablation was performed in the LA in
56 (30%) cases and in the right atrium in 9 (5%).
At the start of the procedure, 112 (60%) patients were
with AF or ﬂutter and a further 23 patients developed
sustained AF intraoperatively. Of these 135 patients, 28
(21%) were ablated to SR but the majority (104, 77%)
were cardioverted either electrically or pharmacologic-
ally. Three patients remained in AF.
Outcomes after a single procedure
Antiarrhythmic medication was continued until the ﬁrst
follow-up appointment (median 3 (IQR 2–3) months
after CA (IQR 2–3)) for 75% of patients (47% amiodar-
one, 17% ﬂecainide, 8% sotalol and 3% others).
Allowing for a 3-month blanking period, 139 (75%)
patients experienced recurrence of AF after a single pro-
cedure during extended follow-up. The initial recur-
rence mechanism was paroxysmal in 55 (39%) patients,
persistent in 81 (58%) and unclear in 4. AF was the
recurrence arrhythmia in 104 (74%) patients with atrial
tachycardia or ﬂutter seen in 29 (21%). The recurrence
arrhythmia was unknown for seven patients. The median
time to ﬁrst recurrence was 210 days (range 91–1850).
A graphical representation of recurrence over time is
shown in ﬁgures 1 and 2. Although ﬁrst recurrence was
seen to occur as late as 5 years after a hitherto successful
procedure, 71% of AF recurrences occurred within the
ﬁrst year following CA and 91% within 2 years.
Regression analysis identiﬁed AF as initial rhythm at
the time of CA (OR 2.05, 95% CI 1.05 to 4.03, p=0.037)
as the only univariable predictor of AF recurrence after
a single procedure, while integration of CT imaging into
3D mapping reduced the risk of recurrence (OR 0.39,
95% CI 0.19 to 0.78, p=0.008). Female sex (p=0.092)
met the prespeciﬁed criteria for inclusion in multivari-
able modelling, but was not conventionally signiﬁcant.
After multivariable analysis, only AF as initial
in-laboratory rhythm (OR 2.59, 95% CI 1.27 to 5.31,
p=0.009) remained a statistically signiﬁcant predictor of
recurrence, and CT integration (OR 0.33, 95% CI 0.16
to 0.69, p=0.003) remained an independent predictor of
success. Details of single procedure univariable and mul-
tivariable analyses are given in table 1.
Outcomes after multiple procedures
In our cohort, patients underwent a mean of 1.75±0.79
procedures (range 1–4). Median follow-up time after
patients’ last CA was 35 months (IQR 15–45). Ninety
(48%) had a further recurrence of AF following their
ﬁnal procedure. Median time to recurrence after the
last procedure was 301 days (range 91–1850). A graph-
ical representation of recurrence over time is shown in
ﬁgure 3. Of those who remained free of recurrence, 31
(32%) remained on class I or III antiarrhythmic drugs.
The only univariable predictor of AF recurrence after
the ﬁnal procedure was age (OR 1.05, 95% CI 1.01 to
1.08, p=0.006). Both female sex (p=0.08) and time (in
months) since ﬁrst diagnosis of AF (p=0.07) also met
the criteria for inclusion in multivariable modelling. CT
integration (OR 0.33, 95% CI 0.18 to 0.61, p<0.001) and
isolation of the pulmonary veins using a WACA tech-
nique (OR 0.49, 95% CI 0.27 to 0.88, p=0.018) were
associated with a lower risk of recurrence. After control-
ling for confounding with multivariable modelling, only
age (OR 1.05, 95% CI 1.01 to 1.09, p=0.018) and lack of
CT integration (OR 0.30, 95% CI 0.15 to 0.60, p=0.001)
remained statistically signiﬁcant in terms of predicting
recurrence.
Long-standing PeAF
The presence of long-standing (>1 year) PeAF has trad-
itionally been associated with poorer outcomes after CA
but was not a predictor of recurrence after single or
multiple procedures in our cohort. To investigate this
further, we performed a subgroup analysis and found
that AF recurrence was no more likely for patients with
long-standing PeAF than for those with shorter duration
PeAF after either a single (73% vs 74%, p=0.9) or ﬁnal
(41% vs 48%, p=0.4) procedure.
Effect of CT integration on freedom from recurrent AF
As shown in tables 1 and 2, integration of CT imaging
into 3D mapping was the only signiﬁcant predictor of
outcome after multivariate modelling after both single
and multiple procedure(s). We therefore undertook sub-
group survival analysis grouping patients according to
use of CT integration during their initial procedure.
AF-free survival was signiﬁcantly increased with CT inte-
gration after both initial (p=0.026) and ﬁnal procedure
(p=0.001) compared with patients whose ablation was
performed without image integration, as shown in ﬁgure
4 (table 3).
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Quality of life after CA of PeAF
As a surrogate for formal quality of life (QoL) measure-
ment, patients’ health status was assessed by the independ-
ent investigators for each follow-up clinic visit. We also
asked patients to rate their own health state at the ﬁnal
telephone follow-up. Overall, 82% of patients felt better in
terms of their arrhythmia with 62% of patients having con-
siderable clinical improvement or arrhythmia cure and a
further 20% gaining at least some improvement. These
proportions did not differ between those cases adjudicated
by the investigators and those reported directly by the
patient. Although three-quarters of patients with ongoing
episodes of AF still gained a beneﬁt in terms of their
health status, patients who remained free from recurrent
AF were signiﬁcantly more likely to gain symptomatic
improvement (75% vs 93%, p<0.001).
Figure 1 The procedural
journey for our cohort of patients
with persistent atrial fibrillation.
Patients underwent a maximum
of four ablations and these are
detailed in the centre of the
diagram as well as the number
with postprocedural recurrence.
To the left are the patients without
recurrence and to the right are
those with recurrence who did not
have further ablation.
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DISCUSSION
There are a number of conclusions to be drawn from
the data presented. First, CA of PeAF is safe with a low
rate of complications. Our 2.1% incidence of major
complications, with no thromboembolic events, com-
pares favourably with that reported in worldwide regis-
tries and other studies.5 13–16 Second, recurrence after
the initial CA is the norm rather than the exception.
Although 2 years’ follow-up is sufﬁcient to observe ∼90%
of AF recurrence, recurrences can occur even after
5 years of remission. After multiple procedures (in our
cohort, the mean number was 1.75, which is lower than
that reported in many other series),16 over half of the
patients can be rendered free of AF. Importantly,
although many patients continue to experience episodes
of AF, the vast majority gain clear symptomatic beneﬁt,
especially if persisting SR is achieved. Finally, there are
few predictors of successful outcome. In our series,
although being in AF was associated with a higher recur-
rence risk after the initial procedure and increased age
predicted poorer long-term success, only integration of
CT imaging into 3D mapping predicted both single and
multiple procedure success.
Few other groups have reported long-term CA out-
comes for large series of patients undergoing CA for
PeAF. The largest reported study contained 676 patients
with non-PAF.17 Success rates of 67% after a single pro-
cedure and 84% after multiple procedures were
reported. However, in contrast to our study, they appear
to have found very few recurrences occurring between
24 and 84 months after either single or multiple proce-
dures, and none later than 32 months. Intensity of
follow-up after the initial 12 months was unclear.
Another leading European centre reported slightly
lower single (20%) and multiple procedure (45%)
success rates compared with our study, but that was in a
population with long-standing PeAF over a slightly
longer follow-up period (56 months).18 They found that
only total AF duration, which was signiﬁcant on univari-
ate but not multivariate analysis in our study, predicted
freedom from AF.
Other studies have generally been of short duration
and/or contained small numbers of patients. In the
largest previously published study from the UK, Hunter
and colleagues reported on 125 patients with PeAF as
part of a larger mixed cohort. Single and multiproce-
dure success rates for PeAF off antiarrhythmic drugs
were 20% and 60%, respectively, over a follow-up period
of 2.7 years.16 An important study by Bertaglia and
colleagues highlighted the importance of long-term
follow-up in this group of patients. In patients who had
already remained in SR for 12 months after their initial
CA, they found an actuarial recurrence rate of 55% at
6 years.9 A recent meta-analysis of long-term CA out-
comes for PeAF has reported 42% (95% CI, 25% to
61%) success after a single procedure and 78% (95% CI
69% to 85%) after multiple procedures but with substan-
tial heterogeneity between studies.19
One of the most striking ﬁndings from our study is
the value of CT integration into a 3D mapping system
in predicting procedural success. Since its introduction,
there has been much interest in image integration
due to the potential beneﬁts of accurate anatomical
visualisation, particularly of anomalous PV arrange-
ments, leading to improved ablation delivery.20 A few
small RCTs and observational studies yielded mixed
results.21–26 A detailed review of these studies highlights
several important limitations. In two of the RCTs in
which no difference in outcome was found, CT imaging
was performed in all patients and was available for
review by operators, thereby negating part of the beneﬁt
of CT integration in recognising variant anatomy.22 24
A meta-analysis showed a non-signiﬁcant reduction in
risk of AF recurrence with image integration (RR=0.76,
Figure 2 Recurrence curve showing number of patients
remaining free from documented recurrence over time after a
single procedure.
Figure 3 Recurrence curve showing number of patients
remaining free from documented recurrence over time after
their last procedure.
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95% CI 0.55 to 1.04, p=0.09).27 Crucially, the ﬁve studies
included in the meta-analysis had follow-up durations of
only 6–12 months. The only previous study with longer
follow-up (283 patients with a median 37 months
follow-up), which was not included in the meta-analysis,
showed a signiﬁcant improvement in single procedure
success with CT integration compared with 3D mapping
alone (p=0.018), in keeping with our ﬁndings.26
The use of implantable loop recorders to monitor for
AF recurrence appears an attractive option, particularly
to help guide decisions about long-term anticoagulation,
etc. However, their use is not without cost and limitations.
Table 2 Logistic regression analysis for recurrence of AF after a single procedure
Univariable Multivariable
Variable p Value OR (95% CI) p Value OR (95% CI)
Age 0.374 1.02 (0.98 to 1.05)
Female sex 0.092 2.59 (0.86 to 7.84) 0.063
Hypertension 0.559 1.22 (0.62 to 2.39)
Body mass index 0.671 0.98 (0.91 to 1.06)
Diabetes 0.388 0.57 (0.16 to 2.04)
LA diameter (mm) 0.564 1.02 (0.95 to 1.09)
Time since diagnosis* 0.985 1.00 (0.99 to 1.01)
Current episode length* 0.406 1.02 (0.98 to 1.06)
Long-standing PeAF 0.776 0.88 (0.37 to 2.10)
General anaesthesia 0.195 2.72 (0.60 to 12.37)
3D mapping 0.989 0.99 (0.30 to 3.24)
CT integration 0.008 0.39 (0.19 to 0.78) 0.003 0.33 (0.16 to 0.69)
WACA 0.349 0.72 (0.36 to 1.44)
Linear ablation 0.775 1.10 (0.56 to 2.19)
CFAE ablation 0.192 1.64 (0.78 to 3.44)
AF as initial rhythm 0.037 2.05 (1.05 to 4.03) 0.009 2.59 (1.27 to 5.31)
Ablate to SR† 0.163 0.52 (0.20 to 1.31)
*Time in months.
†Compared with those cardioverted to SR.
3D, three-dimensional; AF, atrial fibrillation; CFAE, complex fractionated atrial electrogram; LA, left atrial; PeAF, persistent AF; SR, sinus
rhythm; WACA, wide area circumferential ablation.
Table 3 Logistic regression analysis for recurrence of AF after multiple (mean 1.75) procedures
Variable
Univariable Multivariable
p Value OR (95% CI) p Value OR (95% CI)
Age 0.006 1.05 (1.01 to 1.08) 0.018 1.05 (1.01 to 1.09)
Female sex 0.080 2.03 (0.92 to 4.46) 0.424
Hypertension 0.434 1.26 (0.71 to 2.25)
BMI 0.645 0.98 (0.92 to 1.05)
Diabetes 0.479 0.63 (0.18 to 2.24)
LA diameter (mm) 0.800 1.01 (0.95 to 1.06)
Time since diagnosis* 0.071 1.01 (1.00 to 1.01) 0.211
Current episode length* 0.900 1.00 (0.98 to 1.02)
Long-standing PeAF 0.353 0.68 (0.30 to 1.53)
General anaesthesia 0.594 1.31 (0.48 to 3.56)
3D mapping 0.801 0.88 (0.31 to 2.44)
CT integration <0.001 0.33 (0.18 to 0.61) 0.001 0.30 (0.15 to 0.60)
WACA 0.018 0.48 (0.27 to 0.88) 0.370
Linear ablation 0.202 0.68 (0.37 to 1.23)
CFAE ablation 0.755 1.10 (0.60 to 2.03)
AF as initial rhythm 0.938 0.98 (0.54 to 1.76)
Ablate to SR† 0.138 0.51 (0.21 to 1.24)
Time to first recurrence‡ 0.767 1.00 (1.00 to 1.00)
*Time in months.
†Compared with those cardioverted to sinus.
‡For those patients who had a recurrence of AF after their first procedure.
3D, three-dimensional; AF, atrial fibrillation; BMI, body mass index; CFAE, complex fractionated atrial electrogram; LA, left atrial; PeAF,
persistent AF; SR, sinus rhythm; WACA, wide area circumferential ablation.
Wynn GJ, El-Kadri M, Haq I, et al. Open Heart 2016;3:e000394. doi:10.1136/openhrt-2015-000394 7
Arrhythmias and sudden death
This study shows that AF can still recur up to 5 years after
a successful ablation, a time period that exceeds the
battery life of currently available monitors. In addition,
they cannot protect against asymptomatic AF that may
recur between device follow-up appointments. While
their routine use cannot currently be justiﬁed by available
evidence, use in selected patients may be of beneﬁt.
Implications for clinical practice
The term curative AF ablation is often used but, from
our results, would appear to be misleading for PeAF.
Patients must be aware that recurrence is the norm
rather than the exception. Operators may consider
using 3D mapping techniques that combine integration
of CT images, as our results suggest that this has a sig-
niﬁcant impact on long-term success. That notwithstand-
ing, the indication for CA is the relief of AF symptoms
rather than freedom from recurrent AF and our results
show that this is achievable for the majority of patients.
Although previously discouraged as a primary end point
for clinical trials,28 formal assessment of QoL will help
us to better inform patients and make more meaningful
cost-effectiveness analyses than those based purely on
arrhythmic outcome.
Limitations
Since the study was observational, follow-up and man-
agement were decided on clinical grounds by the
responsible physician. As a result, there was some inevit-
able variation in the intensity of follow-up and monitor-
ing and treatment strategies employed. ECGs were
performed for all patients attending follow-up clinics,
but more intense monitoring tended to be dependent
on symptoms, and therefore it is possible that some
patients with asymptomatic paroxysms of AF were
missed. However, the long duration of follow-up and
broad deﬁnition of recurrence go some way towards
mitigating this risk. Our ﬁnal follow-up was by tele-
phone, which may have reduced the accuracy of reports
of recurrence. However, by asking if patients had had an
episode of AF conﬁrmed by a doctor, we attempted to
achieve a similar degree of diagnostic certainty as
required at other follow-up points. We based our QoL
assessment on patients’ reported clinical state rather
than a formal questionnaire that would have provided
more objective information. It cannot be assumed that
the results would have been the same with an anon-
ymised interview/questionnaire. While other long-term
studies have employed similar techniques, it is clearly
suboptimal.16 We have since changed our practice to
collect validated generic and AF-speciﬁc QoL data from
all patients at each clinic visit. Finally, the CA procedures
in our study predated the advent of contact force
sensing technology that may result in more durable
lesions and thus higher success rates for AF ablation
than those found in our study. However, this is an inevit-
able limitation while reporting long-term results of a
rapidly evolving procedure such as CA for AF.
CONCLUSION
CA of PeAF is safe, with a low incidence of major compli-
cations. During long-term follow-up, recurrence of AF is
common, particularly after a single procedure, but
Figure 4 (A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT
integration. (B) Kaplan-Meier curve showing AF-free survival after the final procedure for patients grouped according to use of CT
integration. AF, atrial fibrillation.
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considerable improvements in patient well-being can be
achieved, especially in those who remain free of recur-
rent AF. Use of 3D mapping with CT image integration is
associated with improved procedural success rates.
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